bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
[]
oh forget - below from ritchlin et al as late breaker abst#l02. safe also - some minor candida, rapid as only 16 weeks for primary outcome. #acr22 
not so new at tweeting but always opinionated